Verified against court and regulatory records · No upfront fees · Your information is never sold
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Free · Confidential · About 2 minutes · A case specialist responds within 1 business day
Your answers are never sold or shared without your consent.
The Science Behind Which Cancers Qualify
Not every cancer a Zantac user develops is automatically a Zantac claim. The key question is whether the biological mechanism of NDMA carcinogenesis plausibly explains the development of the specific cancer type, supported by epidemiological evidence of elevated cancer rates in ranitidine users. The organ-specific risk depends heavily on how ranitidine is metabolized and how NDMA is produced and concentrated in the body. NDMA generated in the stomach during ranitidine's acid-mediated degradation directly contacts the gastric mucosa. NDMA absorbed systemically reaches the liver and bloodstream. NDMA filtered by the kidneys concentrates in the bladder during urine storage. These exposure pathways determine which cancers have the strongest scientific case.
Tier 1: Strongest-Supported Cancer Types
Bladder cancer is the cancer with the most consistent epidemiological support in ranitidine litigation. Multiple population-based studies have shown elevated bladder cancer incidence in long-term ranitidine users, consistent with the known NDMA excretion pathway through the urinary tract. Stomach (gastric) cancer and colorectal cancer are also strongly supported — NDMA is generated directly in the gastrointestinal lumen during ranitidine metabolism, placing these tissues in direct contact with the carcinogen at high concentrations. Esophageal cancer has a compelling mechanism as well: ranitidine ingestion and acid reflux events bring ranitidine-containing material into contact with esophageal tissue, and NDMA formation in this context directly exposes the esophageal mucosa.
Tier 2: Additional Qualifying Cancer Types
Breast cancer and prostate cancer are pursued as qualifying cancers in Zantac litigation on the theory of systemic NDMA absorption. After ranitidine is metabolized and NDMA is generated in the gastrointestinal tract, some NDMA is absorbed into the bloodstream and distributed systemically. NDMA is a potent alkylating agent in any tissue it reaches, and breast and prostate tissue exposed through systemic circulation can sustain NDMA-induced DNA damage. These cancers were the subject of heightened scrutiny in the federal MDL Daubert proceedings, but state courts have applied their own standards — several California and Delaware cases involving breast and prostate cancer have proceeded past preliminary causation challenges. Liver cancer and kidney cancer have also been raised but are less common in active litigation.
What If I Have Multiple Risk Factors?
Most cancer patients have more than one potential contributing risk factor — smoking, family history, diet, age, obesity, and alcohol use are common co-factors for the same cancers linked to NDMA. Having other risk factors does not automatically disqualify a claim. In pharmaceutical litigation, the legal theory of causation is typically "substantial contributing cause" — plaintiffs need to demonstrate that ranitidine-associated NDMA was a substantial contributing factor to their cancer, not necessarily the sole or primary cause. Expert witnesses perform differential diagnosis to evaluate and account for other risk factors. The key factors are the duration and consistency of ranitidine use and the biological plausibility of the cancer type relative to the NDMA exposure pathway.
Key data
Data & Statistics
Bladder cancer incidence elevated in long-term ranitidine users in multiple population-based epidemiological studies
Published peer-reviewed epidemiology, 2020-2024
6 primary cancer types accepted in active state court Zantac litigation as of 2026
Delaware and California state court dockets
FAQ
Frequently Asked Questions
Dive deeper
Related Guides
- Zantac NDMA Contamination ExplainedNDMA contamination in Zantac is not an external manufacturing defect — it is an inherent property of the ranitidine molecule itself. Ranitidine is chemically unstable and generates NDMA as a degradation product, and additional NDMA is produced inside the human body during ranitidine metabolism. This made Zantac fundamentally dangerous regardless of which manufacturer produced it.
- The Valisure Study — How the NDMA Problem Was DiscoveredValisure LLC, an independent pharmaceutical testing laboratory in New Haven, Connecticut, discovered the NDMA problem in ranitidine in 2019 and filed a Citizen Petition with the FDA that triggered the events leading to the April 2020 market withdrawal. Valisure's methodology was initially contested but has been substantially vindicated by subsequent independent research.
- Zantac Settlement Expectations — State Court Litigation 2026Zantac state court litigation in 2026 is in an active but early phase compared to fully mature mass torts. Bellwether trials in Delaware will begin to establish settlement values for the broader case pool. Settlement ranges of $200,000 to $3,000,000 are estimated for qualifying claims, with strong Stage IV/wrongful death cases commanding the highest values. Do not expect quick settlements — state court mass torts typically take years.
- Zantac Statute of Limitations — State-by-State 2026 AnalysisThe statute of limitations for Zantac cancer claims varies by state, typically 2 to 3 years from the date of cancer diagnosis or from when the claimant knew or should have known of the Zantac-cancer connection (the discovery rule). The April 2020 FDA withdrawal is often cited as the constructive notice date. Claimants with diagnoses from 2022 onward and those who can show delayed discovery may still have timely claims in 2026.
- Zantac and Bladder CancerBladder cancer is the cancer most strongly and consistently linked to NDMA exposure from ranitidine. NDMA is excreted in urine, directly bathing the bladder epithelium in the carcinogen. Bladder cancer carries a high recurrence rate even after successful treatment, meaning lifetime surveillance and repeat procedures create substantial ongoing medical costs that factor significantly into claim values.
- Zantac Federal MDL Dismissal — What HappenedThe federal MDL in the Southern District of Florida was dismissed in November 2022 after Judge Robin Rosenberg excluded all of the plaintiffs' general causation experts under the Daubert standard. This ruling applies only to federal court. It does not bind state courts. Active Zantac litigation continues in Delaware and California state courts in 2026 under different evidentiary standards.
- Zantac State Court Litigation — Delaware and California 2026Following the closure of the federal MDL in November 2022, Zantac litigation has continued and grown in state courts. Delaware Superior Court is the most active venue, with thousands of consolidated cases proceeding under coordinated case management orders. California state courts have also produced favorable rulings for plaintiffs. State court proceedings are independent of the federal MDL and proceed on their own timelines in 2026.
- Zantac Eligibility RequirementsTo qualify for a Zantac cancer claim in 2026, you generally need: (1) at least 1 year of regular Zantac or ranitidine use; (2) a diagnosis of a qualifying cancer type; (3) a medically plausible timeline between use and diagnosis; and (4) a claim that falls within your state's statute of limitations. State court filings are active in Delaware and California.
- Zantac Brand vs. Generic — All Manufacturers Are LiableThe NDMA problem is inherent to the ranitidine molecule, not to any specific manufacturer or formulation. Branded Zantac (Sanofi, and previously GSK and Pfizer), generic ranitidine from Boehringer Ingelheim and others, and all store-brand versions carry the same risk. All ranitidine manufacturers are named defendants in Zantac litigation.
- FDA Zantac Market Withdrawal — April 2020On April 1, 2020, the FDA formally requested that all ranitidine manufacturers withdraw their products from the U.S. market. This unprecedented action — covering both prescription and OTC products from all manufacturers — marked the FDA's conclusion that the NDMA problem in ranitidine was unfixable and that ranitidine products posed an unacceptable cancer risk for consumers.
- Proving Zantac Use — How to Obtain Pharmacy RecordsPharmacy records are the single strongest form of evidence of long-term Zantac use for litigation purposes. Major pharmacy chains maintain prescription records and often OTC purchase histories for many years. Your attorney can assist in obtaining these records through HIPAA authorizations and subpoenas.
The full investigation